MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Coherus Biosciences Inc

Chiusa

SettoreSettore sanitario

0.86 7.5

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.79

Massimo

0.86

Metriche Chiave

By Trading Economics

Entrata

-5.9M

-57M

Vendite

-47M

7.6M

P/E

Media del settore

1.696

39.564

Margine di Profitto

-744.427

Dipendenti

221

EBITDA

115K

-44M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+437.33% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-32M

87M

Apertura precedente

-6.64

Chiusura precedente

0.86

Notizie sul Sentiment di mercato

By Acuity

41%

59%

127 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Coherus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 lug 2025, 15:46 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250 Million Private Placement

9 lug 2025, 23:44 UTC

Discorsi di Mercato

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 20:26 UTC

Utili

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 lug 2025, 19:18 UTC

Discorsi di Mercato

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 lug 2025, 19:03 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 lug 2025, 18:31 UTC

Discorsi di Mercato

Some Fed Officials Supported Considering July Cut -- Market Talk

9 lug 2025, 17:07 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk -2-

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 lug 2025, 16:14 UTC

Acquisizioni, Fusioni, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 lug 2025, 16:12 UTC

Discorsi di Mercato

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 lug 2025, 16:08 UTC

Discorsi di Mercato

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 lug 2025, 15:31 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250M Private Placement

9 lug 2025, 15:31 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 lug 2025, 15:27 UTC

Discorsi di Mercato

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 lug 2025, 14:36 UTC

Acquisizioni, Fusioni, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 lug 2025, 14:31 UTC

Acquisizioni, Fusioni, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Confronto tra pari

Modifica del prezzo

Coherus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

437.33% in crescita

Previsioni per 12 mesi

Media 4.03 USD  437.33%

Alto 7 USD

Basso 1.05 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

2

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.9209 / 1.05Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

127 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.